论文部分内容阅读
评价德国ASTA药物公司研制的新化疗药物乐铂对小细胞及非小细胞肺癌的治疗效果和不良反应。方法 :治疗原发性支气管肺癌 42例 ,初治 2 5例 ,复治 17例 ;小细胞肺癌 34例 ,非小细胞肺癌 8例。单用乐铂5 0mg m2 静脉滴注 ,共 2个周期 ,2个周期间隔 2 1天。结果 :总有效率 30 9% ,其中部分缓解 (PR) 13例 ;小肺癌有效率 38 2 % ,非小细胞肺癌均无效。该药的剂量限制性毒性为骨髓抑制 ,白细胞、血色素下降轻微 ,Ⅲ—Ⅳ度血小板下降 (周期数 ,下同 )为 4 6 % (1例因血小板下降死亡 ) ,Ⅰ—Ⅱ度下降为 11 8% ,恶心、呕吐发生率 6 4 3% ,均为Ⅰ—Ⅱ度 ,无Ⅲ—Ⅳ度。结论 :乐铂单药治疗对小细胞肺癌疗效较好 ,毒副反应轻 ,主要毒性为血小板降低 ,肾脏毒性不明显 ,本药为临床上治疗小细胞肺癌切实可行的药物
To evaluate the therapeutic effects and adverse reactions of Lebotin, a new chemotherapeutic drug developed by ASTA Pharmaceuticals, Germany, for small cell and non-small cell lung cancer. Methods: 42 cases of primary bronchogenic carcinoma were treated, 25 cases were initially treated, 17 cases retreated, 34 cases of small cell lung cancer, and 8 cases of non-small cell lung cancer. Intravenous infusion of Levoplatin 50 mg m2 alone for 2 cycles with 2 cycles at 2 days intervals. Results: The total effective rate was 30 9%. Among them, 13 patients were partially relieved (PR); the effective rate of small-scale lung cancer was 38 2%, and non-small cell lung cancer was ineffective. The dose-limiting toxicity of the drug was myelosuppression with a slight decrease in white blood cells and hemoglobin, a decrease in III-IV platelet counts (periods, the same below) of 46% (one death due to thrombocytopenia), and a decrease in I-II to 11 In 8%, the incidence of nausea and vomiting was 634%, both of which were I-II degrees, and no III-IV degrees. Conclusion : Letroplatin monotherapy has good curative effect on small cell lung cancer, mild toxicity, the main toxicity is platelet reduction, kidney toxicity is not obvious, this drug is a practical drug for the treatment of small cell lung cancer.